Wednesday, May 28, 2014 12:27:58 PM
Opinion: Mnta does have a technical advantage. I do believe so otherwise why bother.
Fact: Ampha's a-enox approval is not proof of ability but a quirk of the american legal system.At the time there was another competitor I can't remember (a partner of Teva I believe) but they did not choose to go the same way as Ampha to get approval.
Fact: FDA biologics guidance and pathway is still not firm.Bit clearer now than 2 yrs ago but still. Hence mnta is handicapped by this lack of clearance.
Perhaps you could do some more diligence into Ampha's enox approval history(even with their total lack of technical knowledge) and that will shed some light into the current process of biologics generics pathway for approval by the FDA.
FEATURED Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM
Element79 Gold Corp Announces 2024 Clover Work Plans & Nevada Portfolio Updates • ELMGF • Sep 10, 2024 11:00 AM